Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice

Ville Vartiainen; Janne Raula; Luis M. Bimbo; Jenni Viinamäki; Janne T. Backman; Nurcin Ugur; Esko Kauppinen; Eva Sutinen; Emmi Joensuu; Katri Koli; Marjukka Myllärniemi

doi:10.1016/j.ijpharm.2018.04.019

Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice

Ville Vartiainen, Janne Raula, Luis M. Bimbo, Jenni Viinamäki, Janne T. Backman, Nurcin Ugur, Esko Kauppinen, Eva Sutinen, Emmi Joensuu, Katri Koli, Marjukka Myllärniemi

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	International Journal of Pharmaceutics
Volume	544
Issue number	1
Pages (from-to)	121-128
Number of pages	8
ISSN	0378-5173
DOIs	https://doi.org/10.1016/j.ijpharm.2018.04.019
Publication status	Published - 10 Jun 2018
MoE publication type	A1 Journal article-refereed

Fields of Science

317 Pharmacy
3121 General medicine, internal medicine and other clinical medicine
Idiopathic pulmonary fibrosis
Antifibrotics
Tilorone
Dry powder inhaler
AQUEOUS-SOLUTIONS
N-ACETYLCYSTEINE
PROLIFERATION
MODEL
DELIVERY
L-LEUCINE
IN-VITRO CHARACTERIZATION
SALBUTAMOL SULFATE
GAS-PHASE
WORLD EXPERIENCES PIRFENIDONE

Access to Document

10.1016/j.ijpharm.2018.04.019

1-s2.0-S0378517318302321-mainAccepted author manuscript, 1.38 MBLicence: CC BY-NC-ND
1-s2.0-S0378517318302321-mainFinal published version, 1.2 MBLicence: CC BY-NC-ND

Cite this

Vartiainen, V., Raula, J., Bimbo, L. M., Viinamäki, J., Backman, J. T., Ugur, N., Kauppinen, E., Sutinen, E., Joensuu, E., Koli, K., & Myllärniemi, M. (2018). Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice. International Journal of Pharmaceutics, 544(1), 121-128. https://doi.org/10.1016/j.ijpharm.2018.04.019

@article{0fe7a52e440843599716881d5b1cd537,

title = "Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice",

keywords = "317 Pharmacy, 3121 General medicine, internal medicine and other clinical medicine, Idiopathic pulmonary fibrosis, Antifibrotics, Tilorone, Dry powder inhaler, AQUEOUS-SOLUTIONS, N-ACETYLCYSTEINE, PROLIFERATION, MODEL, DELIVERY, L-LEUCINE, IN-VITRO CHARACTERIZATION, SALBUTAMOL SULFATE, GAS-PHASE, WORLD EXPERIENCES PIRFENIDONE",

author = "Ville Vartiainen and Janne Raula and Bimbo, {Luis M.} and Jenni Viinam{\"a}ki and Backman, {Janne T.} and Nurcin Ugur and Esko Kauppinen and Eva Sutinen and Emmi Joensuu and Katri Koli and Marjukka Myll{\"a}rniemi",

year = "2018",

month = jun,

day = "10",

doi = "10.1016/j.ijpharm.2018.04.019",

language = "English",

volume = "544",

pages = "121--128",

journal = "International Journal of Pharmaceutics",

issn = "0378-5173",

publisher = "Elsevier B.V.",

number = "1",

}

Vartiainen, V, Raula, J, Bimbo, LM, Viinamäki, J, Backman, JT, Ugur, N, Kauppinen, E, Sutinen, E, Joensuu, E, Koli, K & Myllärniemi, M 2018, 'Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice', International Journal of Pharmaceutics, vol. 544, no. 1, pp. 121-128. https://doi.org/10.1016/j.ijpharm.2018.04.019

TY - JOUR

T1 - Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice

AU - Vartiainen, Ville

AU - Raula, Janne

AU - Bimbo, Luis M.

AU - Viinamäki, Jenni

AU - Backman, Janne T.

AU - Ugur, Nurcin

AU - Kauppinen, Esko

AU - Sutinen, Eva

AU - Joensuu, Emmi

AU - Koli, Katri

AU - Myllärniemi, Marjukka

PY - 2018/6/10

Y1 - 2018/6/10

KW - 317 Pharmacy

KW - 3121 General medicine, internal medicine and other clinical medicine

KW - Idiopathic pulmonary fibrosis

KW - Antifibrotics

KW - Tilorone

KW - Dry powder inhaler

KW - AQUEOUS-SOLUTIONS

KW - N-ACETYLCYSTEINE

KW - PROLIFERATION

KW - MODEL

KW - DELIVERY

KW - L-LEUCINE

KW - IN-VITRO CHARACTERIZATION

KW - SALBUTAMOL SULFATE

KW - GAS-PHASE

KW - WORLD EXPERIENCES PIRFENIDONE

U2 - 10.1016/j.ijpharm.2018.04.019

DO - 10.1016/j.ijpharm.2018.04.019

M3 - Article

SN - 0378-5173

VL - 544

SP - 121

EP - 128

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

IS - 1

ER -